Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2016

08.09.2016 | Review

The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis

verfasst von: Michael J. Raphael, James J. Biagi, Weidong Kong, Mihaela Mates, Christopher M. Booth, William J. Mackillop

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

It is known that adjuvant chemotherapy improves survival in women with breast cancer. It is not known whether the interval between surgery and the initiation of chemotherapy influences its effectiveness.

Purpose

To determine the relationship between time to initiation of adjuvant chemotherapy and survival in women with breast cancer, through a systematic review of the literature and meta-analysis.

Methods

Systematic review of MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Database of Controlled Trials, Google Scholar, and abstracts presented at major international oncology conferences. The primary meta-analysis included only high-validity studies which directly measured the time from surgery to initiation of adjuvant chemotherapy and which controlled for major prognostic factors. Outcomes reported in the original studies were converted to a regression coefficient (β) and standard error corresponding to a 4-week delay in the initiation of chemotherapy. These relative risks were combined in both fixed- and random-effects models. Homogeneity was assessed by the Cochran χ 2 statistic and the I 2 statistic. Potential publication bias was investigated using standard error-based funnel plots.

Results

Meta-analysis of 8 high-validity studies demonstrated that a 4-week increase in TTAC was associated with a significant increase in the risk of death in both the fixed-effects model (RR 1.04; 95 % CI, 1.01–1.08) and random-effects model (RR 1.08; 95 % CI, 1.01–1.15). The association remained significant when the most highly weighted studies were sequentially removed from this analysis, and also when additional, lower validity studies were included in this analysis. Funnel plots showed no significant asymmetry to suggest publication bias.

Conclusions

Increased waiting time from surgery to initiation of adjuvant chemotherapy is associated with a significant decrease in survival. Avoidance of unnecessary delays in the initiation of adjuvant chemotherapy has the potential to save the lives of many women with breast cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefPubMed
2.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (2012) (EBCTCG). Comparisons between difference polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomized trials. Lancet 379(9814):432–444CrossRef Early Breast Cancer Trialists’ Collaborative Group (2012) (EBCTCG). Comparisons between difference polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomized trials. Lancet 379(9814):432–444CrossRef
4.
Zurück zum Zitat Ng W, Delaney GP, Jacob S, Barton MB (2010) Estimation of an optimal chemotherapy utilisation rate for breast cancer: setting an evidenced-based benchmark for the best-quality cancer care. Eur J Cancer 46(4):703–712CrossRefPubMed Ng W, Delaney GP, Jacob S, Barton MB (2010) Estimation of an optimal chemotherapy utilisation rate for breast cancer: setting an evidenced-based benchmark for the best-quality cancer care. Eur J Cancer 46(4):703–712CrossRefPubMed
5.
Zurück zum Zitat Colleoni M, Gelber RD (2014) Time to initiation of adjuvant chemotherapy for early breast cancer and outcome: the earlier, the better? J Clin Oncol 32(8):717–719CrossRefPubMed Colleoni M, Gelber RD (2014) Time to initiation of adjuvant chemotherapy for early breast cancer and outcome: the earlier, the better? J Clin Oncol 32(8):717–719CrossRefPubMed
6.
Zurück zum Zitat Brooks RJ, Jones SE, Salmon SE et al (1983) Improved outcome with early treatment in an adjuvant breast program. Proc Am Soc Clin Oncol 2 Brooks RJ, Jones SE, Salmon SE et al (1983) Improved outcome with early treatment in an adjuvant breast program. Proc Am Soc Clin Oncol 2
7.
Zurück zum Zitat Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA (1982) Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat 2(2):163–169CrossRefPubMed Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA (1982) Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat 2(2):163–169CrossRefPubMed
8.
Zurück zum Zitat Cold S, During M, Ewertz M, Knoop A, Moller S (2005) Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer 93(6):627–632CrossRefPubMedPubMedCentral Cold S, During M, Ewertz M, Knoop A, Moller S (2005) Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer 93(6):627–632CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Colleoni M, Bonetti M, Coates AS et al (2000) Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 18(3):584–590PubMed Colleoni M, Bonetti M, Coates AS et al (2000) Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 18(3):584–590PubMed
10.
Zurück zum Zitat Downing A, Twelves C, Forman D, Lawrence G, Gilthorpe MS (2014) Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis. Breast J. 20(1):29–36CrossRefPubMed Downing A, Twelves C, Forman D, Lawrence G, Gilthorpe MS (2014) Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis. Breast J. 20(1):29–36CrossRefPubMed
11.
Zurück zum Zitat Farolfi A, Scarpi E, Rocca A et al (2015) Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. Eur J Cancer 51(14):1874–1881CrossRefPubMed Farolfi A, Scarpi E, Rocca A et al (2015) Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. Eur J Cancer 51(14):1874–1881CrossRefPubMed
12.
Zurück zum Zitat Gagliato DM, Gonzalez-Angulo AM, Lei X et al (2014) Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 32(8):735–744CrossRefPubMedCentral Gagliato DM, Gonzalez-Angulo AM, Lei X et al (2014) Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 32(8):735–744CrossRefPubMedCentral
13.
Zurück zum Zitat Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI (2006) Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 99(3):313–321CrossRefPubMed Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI (2006) Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 99(3):313–321CrossRefPubMed
14.
Zurück zum Zitat Alkis N, Durnali AG, Arslan UY et al (2011) Optimal timing of adjuvant treatment in patients with early breast cancer. Med Oncol 28(4):1255–1259CrossRefPubMed Alkis N, Durnali AG, Arslan UY et al (2011) Optimal timing of adjuvant treatment in patients with early breast cancer. Med Oncol 28(4):1255–1259CrossRefPubMed
15.
Zurück zum Zitat Kerbrat P, Roche H, Fumoleau P et al (2005) Does time interval between surgery and adjuvant chemotherapy initiation modify treatment efficacy in operable, breast cancer patients? French Adjuvant Study Group (FASG) results. J Clin Oncol 23 Kerbrat P, Roche H, Fumoleau P et al (2005) Does time interval between surgery and adjuvant chemotherapy initiation modify treatment efficacy in operable, breast cancer patients? French Adjuvant Study Group (FASG) results. J Clin Oncol 23
16.
Zurück zum Zitat Lohrisch C, Paltiel C, Gelmon K et al (2006) Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 24(30):4888–4894CrossRefPubMed Lohrisch C, Paltiel C, Gelmon K et al (2006) Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 24(30):4888–4894CrossRefPubMed
17.
Zurück zum Zitat Nurgalieva ZZ, Franzini L, Morgan RO, Vernon SW, Liu CC, Du XL (2013) Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol 30(1):419CrossRefPubMed Nurgalieva ZZ, Franzini L, Morgan RO, Vernon SW, Liu CC, Du XL (2013) Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol 30(1):419CrossRefPubMed
18.
Zurück zum Zitat Pronzato P, Campora E, Amoroso D et al (1989) Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol 12(6):481–485CrossRefPubMed Pronzato P, Campora E, Amoroso D et al (1989) Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol 12(6):481–485CrossRefPubMed
19.
Zurück zum Zitat Ramjeesingh R, Chen BE, Pater JL et al (2015) Association between definitive surgery and times to administration of adjuvant chemotherapy and outcomes in early breast cancer: analysis of adjuvant studies conducted by NCIC clinical trials groups (NCIC CTG). Cancer Res 75 Ramjeesingh R, Chen BE, Pater JL et al (2015) Association between definitive surgery and times to administration of adjuvant chemotherapy and outcomes in early breast cancer: analysis of adjuvant studies conducted by NCIC clinical trials groups (NCIC CTG). Cancer Res 75
21.
Zurück zum Zitat Altundag MK, Celik I, Ozisik Y (2000) Is there a range of time for initiation of adjuvant chemotherapy in patients with malignancy? Ann Oncol 11(9):1209CrossRefPubMed Altundag MK, Celik I, Ozisik Y (2000) Is there a range of time for initiation of adjuvant chemotherapy in patients with malignancy? Ann Oncol 11(9):1209CrossRefPubMed
22.
Zurück zum Zitat Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH (2016) Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol. 2(3):322–329CrossRefPubMed Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH (2016) Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol. 2(3):322–329CrossRefPubMed
23.
Zurück zum Zitat Ghany DA (2013) Impact of adjuvant chemotherapy delay on survival in cancer breast patients. Chinese–German J Clin Oncol. 12(1):20–24 Ghany DA (2013) Impact of adjuvant chemotherapy delay on survival in cancer breast patients. Chinese–German J Clin Oncol. 12(1):20–24
24.
Zurück zum Zitat Hamid A, White S (2015) P106 Time to adjuvant chemotherapy in high-risk breast cancer: local outcomes and influences. The Breast. 24(Supplement 1):S62CrossRef Hamid A, White S (2015) P106 Time to adjuvant chemotherapy in high-risk breast cancer: local outcomes and influences. The Breast. 24(Supplement 1):S62CrossRef
25.
Zurück zum Zitat Vandergrift JL, Breslin TM, Niland JC et al (2012) The association between timing in adjuvant chemotherapy administration and overall survival for women with breast cancer within the National Comprehensive Cancer Network (NCCN). Cancer Res 72(24 Suppl) Vandergrift JL, Breslin TM, Niland JC et al (2012) The association between timing in adjuvant chemotherapy administration and overall survival for women with breast cancer within the National Comprehensive Cancer Network (NCCN). Cancer Res 72(24 Suppl)
26.
Zurück zum Zitat JaraSanchez C, Ruiz A, Martin M et al (2007) Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: A negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). Breast Cancer Res Treat. 101(2):215–223CrossRef JaraSanchez C, Ruiz A, Martin M et al (2007) Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: A negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). Breast Cancer Res Treat. 101(2):215–223CrossRef
27.
Zurück zum Zitat Samur M, Bozcuk HS, Dalmaz G et al (2002) Treatment delay in breast cancer; does it really have an impact on prognosis. Turk J Cancer 32(4):138–147 Samur M, Bozcuk HS, Dalmaz G et al (2002) Treatment delay in breast cancer; does it really have an impact on prognosis. Turk J Cancer 32(4):138–147
28.
Zurück zum Zitat Seneviratne S, Campbell I, Scott N, Kuper-Hommel M, Round G, Lawrenson R (2014) Ethnic differences in timely adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand: a cohort study. BMC Cancer 14:1CrossRef Seneviratne S, Campbell I, Scott N, Kuper-Hommel M, Round G, Lawrenson R (2014) Ethnic differences in timely adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand: a cohort study. BMC Cancer 14:1CrossRef
29.
Zurück zum Zitat Shannon C, Ashley S, Smith IE (2003) Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol 21(20):3792–3797CrossRefPubMed Shannon C, Ashley S, Smith IE (2003) Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol 21(20):3792–3797CrossRefPubMed
30.
Zurück zum Zitat Trufelli DC, de Matos LL, Santi PX, Del Giglio A (2015) Adjuvant treatment delay in breast cancer patients. Rev Assoc Med Bras 61(5):411–416CrossRefPubMed Trufelli DC, de Matos LL, Santi PX, Del Giglio A (2015) Adjuvant treatment delay in breast cancer patients. Rev Assoc Med Bras 61(5):411–416CrossRefPubMed
31.
Zurück zum Zitat Yu KD, Huang S, Zhang JX, Liu GY, Shao ZM (2013) Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC Cancer 13:240CrossRefPubMedPubMedCentral Yu KD, Huang S, Zhang JX, Liu GY, Shao ZM (2013) Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC Cancer 13:240CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Vandergrift JL, Niland JC, Theriault RL et al (2013) Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst 105(2):104–112CrossRefPubMedPubMedCentral Vandergrift JL, Niland JC, Theriault RL et al (2013) Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst 105(2):104–112CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG (2009) PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269CrossRefPubMed Moher D, Liberati A, Tetzlaff J, Altman DG (2009) PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269CrossRefPubMed
34.
Zurück zum Zitat Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRefPubMed Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRefPubMed
35.
Zurück zum Zitat Greenland S (1994) Quality scores are useless and potentially misleading. Am J Epidemiol 140:300–301 Greenland S (1994) Quality scores are useless and potentially misleading. Am J Epidemiol 140:300–301
36.
Zurück zum Zitat Juni P, Witschi A, Bloch R, Egger M (1999) The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282(11):1054–1060CrossRefPubMed Juni P, Witschi A, Bloch R, Egger M (1999) The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282(11):1054–1060CrossRefPubMed
37.
Zurück zum Zitat Stang A (2010) Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605CrossRefPubMed Stang A (2010) Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605CrossRefPubMed
38.
Zurück zum Zitat Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud P (2014) Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA 312(6):623–630CrossRefPubMed Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud P (2014) Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA 312(6):623–630CrossRefPubMed
39.
Zurück zum Zitat Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM (2011) Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 305(22):2335–2342CrossRefPubMed Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM (2011) Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 305(22):2335–2342CrossRefPubMed
40.
Zurück zum Zitat Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ (2008) The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol 87(1):3–16CrossRefPubMed Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ (2008) The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol 87(1):3–16CrossRefPubMed
41.
Zurück zum Zitat Schrag D, Cramer LD, Bach PB, Begg CB (2001) Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 93(11):850–857CrossRefPubMed Schrag D, Cramer LD, Bach PB, Begg CB (2001) Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 93(11):850–857CrossRefPubMed
42.
Zurück zum Zitat Savovic J, Jones HE, Altman DG et al (2012) Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 157(6):429–438CrossRefPubMed Savovic J, Jones HE, Altman DG et al (2012) Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 157(6):429–438CrossRefPubMed
43.
Zurück zum Zitat Greenland S, O’Rourke K (2008) Meta-analysis. In: Rothman KJ, Greenland S, Lash TL (eds) Modern epidemiology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia Greenland S, O’Rourke K (2008) Meta-analysis. In: Rothman KJ, Greenland S, Lash TL (eds) Modern epidemiology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia
44.
Zurück zum Zitat Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135(11):1301–1309PubMed Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135(11):1301–1309PubMed
45.
Zurück zum Zitat Cooper H, Hedges LV, Valentin JC (2009) The handbook of research synthesis and meta-analysis, 2nd edn. Russell Sage Foundation, New York Cooper H, Hedges LV, Valentin JC (2009) The handbook of research synthesis and meta-analysis, 2nd edn. Russell Sage Foundation, New York
46.
47.
Zurück zum Zitat Sackett DL (1986) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 89(2 Suppl):2S–3SCrossRefPubMed Sackett DL (1986) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 89(2 Suppl):2S–3SCrossRefPubMed
48.
Zurück zum Zitat Sackett D, Haynes BR, Guyatt GH, Tugwell P (1991) Deciding whether your treatment has done harm, 2nd edn. Little Brown and Company, Boston Sackett D, Haynes BR, Guyatt GH, Tugwell P (1991) Deciding whether your treatment has done harm, 2nd edn. Little Brown and Company, Boston
50.
51.
Zurück zum Zitat Schatten WE (1958) An experimental study of postoperative tumor metastases. I. Growth of pulmonary metastases following total removal of primary leg tumor. Cancer 11(3):455–459CrossRefPubMed Schatten WE (1958) An experimental study of postoperative tumor metastases. I. Growth of pulmonary metastases following total removal of primary leg tumor. Cancer 11(3):455–459CrossRefPubMed
52.
Zurück zum Zitat Gunduz N, Fisher B, Saffer EA (1979) Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 39(10):3861–3865PubMed Gunduz N, Fisher B, Saffer EA (1979) Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 39(10):3861–3865PubMed
53.
Zurück zum Zitat O’Reilly MS, Boehm T, Shing Y et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277–285CrossRefPubMed O’Reilly MS, Boehm T, Shing Y et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277–285CrossRefPubMed
54.
Zurück zum Zitat O’Reilly MS, Holmgren L, Shing Y et al (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79(2):315–328CrossRefPubMed O’Reilly MS, Holmgren L, Shing Y et al (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79(2):315–328CrossRefPubMed
Metadaten
Titel
The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis
verfasst von
Michael J. Raphael
James J. Biagi
Weidong Kong
Mihaela Mates
Christopher M. Booth
William J. Mackillop
Publikationsdatum
08.09.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2016
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3960-3

Weitere Artikel der Ausgabe 1/2016

Breast Cancer Research and Treatment 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.